New radioactive drug targets Hard-to-Treat cancers in first human study

NCT ID NCT06639191

Recruiting now Disease control Sponsor: Karolinska University Hospital Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated May 24, 2026 · Updated 19 times

Summary

This early-phase study tests a new radioactive drug, [177Lu]Lu-AKIR001, in 15 adults with advanced solid tumors (like thyroid, head and neck, cervical, vulvar, or lung cancer) that have a specific marker called CD44v6 and have stopped responding to standard treatments. The main goal is to see if the drug is safe and what side effects it causes. Participants receive up to four infusions of the drug, with close monitoring for 6 to 12 weeks after each dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID GLAND ANAPLASTIC CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Karolinska University hospital
RECRUITING

Stockholm, Stockholm County, 17176, Sweden

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CANCER HEAD AND NECK CERVIX CARCINOMA NON-SMALL CELL LUNG CANCER STAGE IV NON-SMALL CELL LUNG CANCER STAGE IV POORLY DIFFERENTIATED THYROID CARCINOMA POORLY DIFFERENTIATED THYROID CARCINOMA THYROID GLAND ANAPLASTIC CARCINOMA VULVAR CANCER, STAGE IV VULVAR CANCER, STAGE IV VULVAR CANCER, STAGE IV